Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Supernus Pharm
(NQ:
SUPN
)
34.55
+0.30 (+0.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Supernus Pharm
< Previous
1
2
3
4
Next >
Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call Transcript
November 04, 2021
SUPN earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Supernus Pharmaceuticals: Q3 Earnings Insights
November 03, 2021
Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
Why Supernus' Acquisition of Adamas Is a Smart Move
October 21, 2021
Adamas looks like a good fit for Supernus.
Via
The Motley Fool
Earnings Scheduled For May 5, 2021
May 05, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
Earnings Scheduled For November 3, 2021
November 03, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
October 11, 2021
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
October 11, 2021
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
October 11, 2021
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News
October 11, 2021
ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million.
Via
InvestorPlace
Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights
October 11, 2021
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has agreed to acquire Adamas Pharmaceuticals Inc (NASDAQ: ADMS) for $9.10 per share, or $450 million. The deal...
Via
Benzinga
Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization
August 16, 2021
Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What...
Via
Benzinga
Exposures
COVID-19
Supernus Pharmaceuticals, inc (SUPN) Q2 2021 Earnings Call Transcript
August 04, 2021
SUPN earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
June 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,...
Via
Benzinga
Exposures
COVID-19
Earnings Scheduled For August 4, 2021
August 04, 2021
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to...
Via
Benzinga
Biotechs Ready To Roar
June 13, 2021
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector...
Via
Talk Markets
Exposures
Product Safety
Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure
June 10, 2021
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Supernus Pharmaceuticals Inc (SUPN) Q1 2021 Earnings Call Transcript
May 05, 2021
SUPN earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
May 01, 2021
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid...
Via
Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
April 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Ardelyx, Inc. (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
April 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Exposures
COVID-19
Stocks That Hit 52-Week Highs On Wednesday
April 14, 2021
During Wednesday's morning session, 226 stocks hit new 52-week highs. Noteables: The largest company by market cap to set a new 52-week high was NVIDIA (NASDAQ:...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2021
April 13, 2021
Upgrades For Booking Holdings Inc (NASDAQ:BKNG), Jefferies upgraded the previous rating of Hold to Buy. In the fourth quarter, Booking Holdings showed an EPS of $0.57,...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.